Ipsen SA (IPN)

87.42
+0.48(+0.55%)
  • Volume:
    11,519
  • Bid/Ask:
    0.00/0.00
  • Day's Range:
    86.80 - 87.50
  • Type:Equity
  • Market:France
  • ISIN:FR0010259150

IPN Overview

Prev. Close
86.94
Day's Range
86.8-87.5
Revenue
2.79B
Open
87.18
52 wk Range
65.9-93.14
EPS
7.49
Volume
11,519
Market Cap
7.17B
Dividend (Yield)
1.00
(1.15%)
Average Volume (3m)
84,924
P/E Ratio
11.61
Beta
0.79
1-Year Change
20.92%
Shares Outstanding
82,242,676
Next Earnings Date
11 Feb 2022
What is your sentiment on Ipsen SA?
or
Vote to see community's results!

Ipsen SA Company Profile

Employees
5703
Market
France

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, gastroenterology, cognitive disorders, and rare diseases. It offers Somatuline for neuroendocrine tumors and acromegaly; Decapeptyl for metastatic prostate cancer, uterine fibroids, precocious puberty, endometriosis, female sterility, and early stage breast cancer; Cabometyx for renal cell and second-line hepatocellular carcinoma; Onivyde for second-line metastatic pancreatic cancer; Dysport for motor muscular disorders and medical aesthetics; NutropinAq for growth failure in children due to growth hormone (GH) deficiency, turner syndrome, and chronic renal failure, as well as GH deficiency in adults; and Increlex for growth failure in children and adolescents. It offers Smecta for chronic and acute diarrhea, and pain associated with functional bowel diseases; Forlax for constipation; Fortrans/Eziclen for bowel cleansing prior to endoscopy, X-ray examination, and colonic surgery; and Tanakan for cognitive disorders in adults, vertigo of vestibular origin and vestibular rehabilitation, and tinnitus. The company provides Xermelo for the carcinoid syndrome; Cometriq for medullary thyroid cancer; Smebiocta/SmectaFlora Comfort, a food supplement; SmectaGas, a medical device used in the symptomatic treatment of gas-related gastrointestinal disorders and relief of gas-related symptoms; and Etiasa for inflammatory bowel diseases. It offers other consumer healthcare products in the gastro-intestinal area, including Buscopan, Clin4000, Prontalgine, Suppositoria Glycerini, Mucothiol, Floractin, and Mucodyne. The company has agreements with Debiopharm, Exelixis, Galderma, Blueprint Medicines, TerSera Therapeutics, Rhythm Pharmaceuticals, Teijin, Braintree Laboratories, Ethypharm, Schwabe, BAKX Therapeutics Inc., and Exicure. Ipsen S.A. was founded in 1929 and is headquartered in Boulogne-Billancourt, France. Ipsen S.A. is a subsidiary of Mayroy SA.

Read More

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyBuyNeutralStrong Buy
Technical IndicatorsStrong BuyStrong BuyStrong BuyStrong SellStrong Buy
SummaryStrong BuyStrong BuyStrong BuySellStrong Buy
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.